In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci

Infection

Volumn 28, Issue 4, 2000, Pages 214-218

  Al Nawas, B ^a   Swantes, J ^b   Shah, P M ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Enterococci; In vitro activity; LY333328; Vancomycin; VRE

Indexed keywords

ANTIBIOTIC AGENT; GLYCOPEPTIDE; ORITAVANCIN; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL INFECTION; DRUG ACTIVITY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HUMAN; HUMAN CELL; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; NORMAL HUMAN; PHAGOCYTE;

ANTI-BACTERIAL AGENTS; CELL CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN RESISTANCE;

EID: 0033860806     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s150100070038     Document Type: Article

References (13)

1. 1. Jones RN, Sader HS, Erwin ME, Anderson SC: Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. Diagn Microbiol Infect Dis 1995; 21: 85-93.
2. 2. Kresken M, Hafner D: Prävalenz der Antibiotikaresistenz bei klinisch wichtigen Infektionserregern in Mitteleuropa. Chemotherapie Journal 1996; 5: 225-230.
3. 3. Fuller RE, Drew RH, Perfect JR: Treatment of vancomycin-resistant enterococci, with a focus on quinupristin-dalfopristin. Pharmacotherapy 1996; 16: 584-592.
4. 4. Cooper RD, Snyder NJ, Zweifel MJ, Staszak MA, Wilkie SC, Nicas TI, Mullen DL, Butler TF, Rodriguez MJ, Huff BE, Thompson RC: Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot Tokyo 1996; 49: 575-581.
5. 5. Garcia-Garrote F, Cercenado E, Alcala L, Bouza E: In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates. Antimicrob Agents Chemother 1998; 42: 2452-2455.
6. 6. Jones RN, Barret MS, Erwin ME: In vitro activity and spectrum of LY 333328, a novel glycopeptide derivative. Antimicrob Agents Chemother 1997; 41: 488-493.
7. 7. Tulkens PM: Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis 1991; 10: 100-106.
8. 8. Thomasson HR, Phillips D, Smith BP, Chien JY: Pharmacokinetics and safety of multiple intravenous doses of LY333328 diphosphate in healthy men. (abstr) Clin Microb Inf 1999; 5 (suppl 3): 135-136.
9. 9. Al-Nawas B, Shah PM: In vitro activity of new macrolides against intracellular staphylococci. Rev Esp Quimoterap 1996; 9: 126-129.
10. 10. Fietta A, Merlini C, Gialdroni Grassi G. Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. Chemotherapy 1997; 9: 23-31.
11. 11. Paul TR, Knight ST, Raulston JE, Wyrick PB: Delivery of azithromycin to Chlamydia trachomatis-infected polarized human endometrial epithelial cells by polymorphonuclear leucocytes. J Antimicrob Chemother 1997; 39: 623-630.
12. 12. Herrera-lnsua I, Jacques-Palaz K, Murray BE, Rakita RM: Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium. Antimicrob Agents Chemother 1996; 40: 886-890.
13. 13. Al-Nawas B, Shah PM: Intracellular activity of vancomycin and LY333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus. Infection 1998; 26: 165-167.